- Becton, Dickinson and Company ( NYSE: BDX ), or BD, and CerTest Biotec on Wednesday said their monkeypox PCR detection test was now commercially available outside of the U.S. for use in research applications by laboratories.
- The test, called the CerTest VIASURE Monkeypox molecular test, was developed using the BD MAX System.
- "Speed is of the essence when responding to what the World Health Organization has declared a global health emergency," said CerTest Biotec managing director Nelson Fernandes. "We hope this new test will boost capacity for monkeypox research, ultimately helping quell the spread of the disease."
- The WHO designated the current monkeypox outbreak a public health emergency of international concern on Saturday.
- BDX stock closed +0.6% at $244.15 on Tuesday.
For further details see:
BD, CerTest Biotec announce commercial launch of monkeypox test